[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586935":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":195,"collaborators":19,"id":197,"slug":198,"hasResults":199,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":19,"eligibilityCriteria":203,"healthyVolunteers":199,"sex":204,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":19,"studyType":210,"phases":211,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},{"fullName":5,"class":6},"UCB Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Bimekizumab","EXPERIMENTAL","Study participants will receive a bimekizumab dose which is weight-dependent.",[13],"Drug: Bimekizumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Bimekizumab will be administered at pre-specified timepoints.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"UCB Cares","001 844 599 2273","STUDY_DIRECTOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","+18445992273","ucbcares@ucb.com",{"name":22,"role":27,"phone":23,"phoneExt":19,"email":19},[32,46,56,66,76,86,96,106,110,119,129,139,149,159,167,177,182,190],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":19},"Hs0006 50175","RECRUITING","Phoenix","Arizona","85006","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-112.07404,33.44838,{"lat":44,"lon":43},{"facility":47,"status":34,"city":48,"state":49,"zip":50,"country":38,"countryCode":39,"cosmosGeoPoint":51,"geoPoint":55,"contacts":19},"Hs0006 50708","Roseville","California","95661",{"type":41,"coordinates":52},[53,54],-121.28801,38.75212,{"lat":54,"lon":53},{"facility":57,"status":58,"city":59,"state":49,"zip":60,"country":38,"countryCode":39,"cosmosGeoPoint":61,"geoPoint":65,"contacts":19},"Hs0006 50684","ACTIVE_NOT_RECRUITING","Sacramento","95815",{"type":41,"coordinates":62},[63,64],-121.4944,38.58157,{"lat":64,"lon":63},{"facility":67,"status":34,"city":68,"state":69,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":19},"Hs0006 50707","Washington D.C.","District of Columbia","20010",{"type":41,"coordinates":72},[73,74],-77.03637,38.89511,{"lat":74,"lon":73},{"facility":77,"status":34,"city":78,"state":79,"zip":80,"country":38,"countryCode":39,"cosmosGeoPoint":81,"geoPoint":85,"contacts":19},"Hs0006 50199","Miami","Florida","33136",{"type":41,"coordinates":82},[83,84],-80.19366,25.77427,{"lat":84,"lon":83},{"facility":87,"status":34,"city":88,"state":89,"zip":90,"country":38,"countryCode":39,"cosmosGeoPoint":91,"geoPoint":95,"contacts":19},"Hs0006 50712","Bowling Green","Kentucky","42104",{"type":41,"coordinates":92},[93,94],-86.4436,36.99032,{"lat":94,"lon":93},{"facility":97,"status":34,"city":98,"state":99,"zip":100,"country":38,"countryCode":39,"cosmosGeoPoint":101,"geoPoint":105,"contacts":19},"Hs0006 50178","Clarkston","Michigan","48346",{"type":41,"coordinates":102},[103,104],-83.41883,42.73586,{"lat":104,"lon":103},{"facility":107,"status":34,"city":108,"state":99,"zip":109,"country":38,"countryCode":39,"cosmosGeoPoint":19,"geoPoint":19,"contacts":19},"Hs0006 50710","Fort Gratiot","48059",{"facility":111,"status":34,"city":112,"state":99,"zip":113,"country":38,"countryCode":39,"cosmosGeoPoint":114,"geoPoint":118,"contacts":19},"Hs0006 50711","Troy","48084",{"type":41,"coordinates":115},[116,117],-83.14993,42.60559,{"lat":117,"lon":116},{"facility":120,"status":34,"city":121,"state":122,"zip":123,"country":38,"countryCode":39,"cosmosGeoPoint":124,"geoPoint":128,"contacts":19},"Hs0006 50706","Chapel Hill","North Carolina","27516",{"type":41,"coordinates":125},[126,127],-79.05584,35.9132,{"lat":127,"lon":126},{"facility":130,"status":34,"city":131,"state":132,"zip":133,"country":38,"countryCode":39,"cosmosGeoPoint":134,"geoPoint":138,"contacts":19},"Hs0006 50202","Fairborn","Ohio","45324",{"type":41,"coordinates":135},[136,137],-84.01938,39.82089,{"lat":137,"lon":136},{"facility":140,"status":34,"city":141,"state":142,"zip":143,"country":38,"countryCode":39,"cosmosGeoPoint":144,"geoPoint":148,"contacts":19},"Hs0006 50201","Arlington","Texas","76011",{"type":41,"coordinates":145},[146,147],-97.10807,32.73569,{"lat":147,"lon":146},{"facility":150,"status":34,"city":151,"state":19,"zip":19,"country":152,"countryCode":153,"cosmosGeoPoint":154,"geoPoint":158,"contacts":19},"Hs0006 40326","Berlin","Germany","DE",{"type":41,"coordinates":155},[156,157],13.41053,52.52437,{"lat":157,"lon":156},{"facility":160,"status":34,"city":161,"state":19,"zip":19,"country":152,"countryCode":153,"cosmosGeoPoint":162,"geoPoint":166,"contacts":19},"Hs0006 40747","Mainz",{"type":41,"coordinates":163},[164,165],8.28008,49.98185,{"lat":165,"lon":164},{"facility":168,"status":34,"city":169,"state":19,"zip":19,"country":170,"countryCode":171,"cosmosGeoPoint":172,"geoPoint":176,"contacts":19},"Hs0006 40625","Warsaw","Poland","PL",{"type":41,"coordinates":173},[174,175],21.01178,52.22977,{"lat":175,"lon":174},{"facility":178,"status":34,"city":169,"state":19,"zip":19,"country":170,"countryCode":171,"cosmosGeoPoint":179,"geoPoint":181,"contacts":19},"Hs0006 40761",{"type":41,"coordinates":180},[174,175],{"lat":175,"lon":174},{"facility":183,"status":34,"city":184,"state":19,"zip":19,"country":170,"countryCode":171,"cosmosGeoPoint":185,"geoPoint":189,"contacts":19},"Hs0006 40095","Wroclaw",{"type":41,"coordinates":186},[187,188],17.03006,51.10286,{"lat":188,"lon":187},{"facility":191,"status":34,"city":184,"state":19,"zip":19,"country":170,"countryCode":171,"cosmosGeoPoint":192,"geoPoint":194,"contacts":19},"Hs0006 40845",{"type":41,"coordinates":193},[187,188],{"lat":188,"lon":187},{"type":196,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100586935","phase-3-a-study-to-assess-the-pharmacokinetics-and-safety-of-bimekizumab-in-children-and-adolescents-with-moderate-to-severe-hidradenitis-suppurativa-100586935",false,"NCT06921850","A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa","A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Study participant must be 12 to \\\u003C18 years of age at the time of informed consent\u002Fassent, at Tanner stage 2 or more, for the first 8 participants only, followed by also including participants ≥9 to \\\u003C18 years of age at Tanner stage 2 or more.\n* Study participant must have a diagnosis of HS for at least 6 months prior to the Baseline Visit.\n* Study participant must have moderate to severe HS, defined as a total of ≥5 inflammatory lesions (ie, the sum of abscesses and inflammatory nodules), as assessed at both the Screening and Baseline Visits.\n* Study participant must have HS lesions present in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or III, as assessed at both the Screening and Baseline Visits.\n* Study participant must have had a history of inadequate response to a course of a systemic antibiotic for treatment of HS\n* Study participant must weigh ≥30kg at the Screening Visit.\n\nExclusion Criteria:\n\n* Study participant has a draining tunnel count of \\>20 at either the Screening or Baseline Visits.\n* Study participant has experienced primary failure (no response within 12 weeks) to 1 or more IL 17 biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier.\n* Study participant has previously participated in this study or has received previous therapy with bimekizumab.\n* Study participant has a history of IBD or symptoms suggestive of IBD.\n* History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated\n* Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)\n* Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments\n* Study participant has the presence of active suicidal ideation, or positive suicide behavior,\n* Study participant diagnosed with severe depression in the past 6 months prior to the Screening Visit.\n* Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study.","ALL","9 Years","17 Years",{"count":208,"type":209},40,"ESTIMATED","INTERVENTIONAL",[212],"PHASE3","The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)",[215],"Hidradenitis Suppurativa",[9,217,215],"HS","2026-06-18",{"date":220,"type":221},"2026-06-22","ACTUAL",{"date":223,"type":221},"2025-04-07",{"date":225,"type":209},"2029-03-06",{"name":227,"class":6},"UCB Biopharma SRL",18]